These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 14613272)

  • 1. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A; Williams GW; McKenna F; Fort JG
    Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
    Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
    Schnitzer TJ; Kivitz AJ; Lipetz RS; Sanders N; Hee A
    Arthritis Rheum; 2005 Dec; 53(6):827-37. PubMed ID: 16342089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
    Emkey R; Rosenthal N; Wu SC; Jordan D; Kamin M;
    J Rheumatol; 2004 Jan; 31(1):150-6. PubMed ID: 14705234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
    Smugar SS; Schnitzer TJ; Weaver AL; Rubin BR; Polis AB; Tershakovec AM
    Curr Med Res Opin; 2006 Jul; 22(7):1353-67. PubMed ID: 16834834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial.
    Malmstrom K; Daniels S; Kotey P; Seidenberg BC; Desjardins PJ
    Clin Ther; 1999 Oct; 21(10):1653-63. PubMed ID: 10566562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
    Ehrich EW; Bolognese JA; Watson DJ; Kong SX
    Am J Manag Care; 2001 Jun; 7(6):609-16. PubMed ID: 11439734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
    J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
    Kivitz A; Fairfax M; Sheldon EA; Xiang Q; Jones BA; Gammaitoni AR; Gould EM
    Clin Ther; 2008 Dec; 30(12):2366-77. PubMed ID: 19167595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
    Ehrich EW; Davies GM; Watson DJ; Bolognese JA; Seidenberg BC; Bellamy N
    J Rheumatol; 2000 Nov; 27(11):2635-41. PubMed ID: 11093446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
    J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
    Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
    Cannon GW; Caldwell JR; Holt P; McLean B; Seidenberg B; Bolognese J; Ehrich E; Mukhopadhyay S; Daniels B
    Arthritis Rheum; 2000 May; 43(5):978-87. PubMed ID: 10817549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
    JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints.
    Bolognese JA; Ehrich EW; Schnitzer TJ
    J Rheumatol; 2001 Dec; 28(12):2700-4. PubMed ID: 11764220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
    Detora LM; Krupa D; Bolognese J; Sperling RS; Ehrich EW
    J Rheumatol; 2001 Nov; 28(11):2494-503. PubMed ID: 11708424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis.
    Dahlberg LE; Holme I; Høye K; Ringertz B
    Scand J Rheumatol; 2009; 38(2):133-43. PubMed ID: 19165648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.